The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Dec 23

PMID 36559025

Authors

Evgeny Bazdyrev

Maria Panova

Valeria Zherebtsova

Alexandra Burdenkova

Ivan Grishagin

Fedor Novikov

Vladimir Nebolsin

Affiliations

Soon will be listed here.

Abstract

Since the beginning of the COVID-19 pandemic, clinical, radiological, and histopathological studies have provided evidence that organizing pneumonia is a possible consequence of the SARS-CoV2 infection. This post-COVID-19 organizing pneumonia (PCOP) causes persisting dyspnea, impaired pulmonary function, and produces radiological abnormalities for at least 5 weeks after onset of symptoms. While most patients with PCOP recover within a year after acute COVID-19, 5-25% of cases need specialized treatment. However, despite substantial resources allocated worldwide to finding a solution to this problem, there are no approved treatments for PCOP. Oral corticosteroids produce a therapeutic response in a majority of such PCOP patients, but their application is limited by the anticipated high-relapse frequency and the risk of severe adverse effects. Herein, we conduct a systematic comparison of the epidemiology, pathogenesis, and clinical presentation of the organizing pneumonias caused by COVID-19 as well as other viral infections. We also use the clinical efficacy of corticosteroids in other postinfection OPs (PIOPs) to predict the therapeutic response in the treatment of PCOP. Finally, we discuss the potential application of a candidate anti-inflammatory and antifibrotic therapy for the treatment of PCOP based on the analysis of the latest clinical trials data.

Citing Articles

Management of Severe SARS-CoV-2-Associated Organizing Pneumonia With Immunoglobulins.

Akpa B Cureus. 2025; 17(1):e77120.

PMID: 39925611 PMC: 11806400. DOI: 10.7759/cureus.77120.

Evaluation of diseases complicating long COVID: A retrospective chart review.

Tsuchida T, Hirose M, Fujii H, Hisatomi R, Ishizuka K, Inoue Y J Gen Fam Med. 2024; 25(6):324-332.

PMID: 39554298 PMC: 11565060. DOI: 10.1002/jgf2.716.

Nasrullah A, Shakir H, Khan E, Bilal M, Sheikh A, Malik K J Community Hosp Intern Med Perspect. 2024; 14(5):63-72.

PMID: 39399191 PMC: 11466343. DOI: 10.55729/2000-9666.1399.

Corticosteroid Therapy Duration and Dosage According to the Timing of Treatment Initiation for Post-COVID-19 Organizing Pneumonia.

Yoon C, Park H, Lee J, Kho B, Kim T, Shin H Chonnam Med J. 2024; 60(3):166-173.

PMID: 39381118 PMC: 11458313. DOI: 10.4068/cmj.2024.60.3.166.

The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia.

Hong H, Choi S, Jeon Y, Kim T, Kim S, An T Infect Chemother. 2024; 56(3):378-385.

PMID: 39370123 PMC: 11458498. DOI: 10.3947/ic.2024.0046.

References

Littlefield K, Watson R, Schneider J, Neff C, Yamada E, Zhang M . SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022; 18(5):e1010359. PMC: 9176759. DOI: 10.1371/journal.ppat.1010359. View

Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

Baha A, Yildirim F, Kokturk N, Galata Z, Akyurek N, Demirci N . Cryptogenic and Secondary Organizing Pneumonia: Clinical Presentation, Radiological and Laboratory Findings, Treatment, and Prognosis in 56 Cases. Turk Thorac J. 2018; 19(4):201-208. PMC: 6196895. DOI: 10.5152/TurkThoracJ.2018.18008. View

Izadi M, Cegolon L, Javanbakht M, Sarafzadeh A, Abolghasemi H, Alishiri G . Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review. Int Immunopharmacol. 2021; 92:107307. PMC: 7752030. DOI: 10.1016/j.intimp.2020.107307. View

Ojo A, Balogun S, Williams O, Ojo O . Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med. 2020; 2020:6175964. PMC: 7439160. DOI: 10.1155/2020/6175964. View

Kloka J, Blum L, Old O, Zacharowski K, Friedrichson B . Characteristics and mortality of 561,379 hospitalized COVID-19 patients in Germany until December 2021 based on real-life data. Sci Rep. 2022; 12(1):11116. PMC: 9247915. DOI: 10.1038/s41598-022-15287-3. View

Maiuolo J, Mollace R, Gliozzi M, Musolino V, Carresi C, Paone S . The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. Int J Mol Sci. 2020; 21(23). PMC: 7730352. DOI: 10.3390/ijms21239309. View

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View

Chirumbolo S, Valdenassi L, Simonetti V, Bertossi D, Ricevuti G, Franzini M . Insights on the mechanisms of action of ozone in the medical therapy against COVID-19. Int Immunopharmacol. 2021; 96:107777. PMC: 8112288. DOI: 10.1016/j.intimp.2021.107777. View

10.

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

11.

Montazersaheb S, Hosseiniyan Khatibi S, Hejazi M, Tarhriz V, Farjami A, Ghasemian Sorbeni F . COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022; 19(1):92. PMC: 9134144. DOI: 10.1186/s12985-022-01814-1. View

12.

Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q . Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020; 127:104371. PMC: 7195434. DOI: 10.1016/j.jcv.2020.104371. View

13.

Pannone G, Caponio V, De Stefano I, Ramunno M, Meccariello M, Agostinone A . Lung histopathological findings in COVID-19 disease - a systematic review. Infect Agent Cancer. 2021; 16(1):34. PMC: 8127295. DOI: 10.1186/s13027-021-00369-0. View

14.

Zhang F, Wei Y, He L, Zhang H, Hu Q, Yue H . A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019. Chin Med J (Engl). 2021; 135(3):368-370. PMC: 8812696. DOI: 10.1097/CM9.0000000000001614. View

15.

Meduri G . The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J. 1996; 9(12):2650-70. DOI: 10.1183/09031936.96.09122650. View

16.

Schlesinger C, Koss M . The organizing pneumonias: an update and review. Curr Opin Pulm Med. 2005; 11(5):422-30. DOI: 10.1097/01.mcp.0000175521.41729.07. View

17.

Gentile P, Sterodimas A . Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020; 20(7):711-716. PMC: 7196919. DOI: 10.1080/14712598.2020.1761322. View

18.

Onishi Y, Kawamura T, Higashino T, Mimura R, Tsukamoto H, Sasaki S . Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. PLoS One. 2021; 16(4):e0249300. PMC: 8016294. DOI: 10.1371/journal.pone.0249300. View

19.

Beom Park W, Jun K, Kim G, Choi J, Rhee J, Cheon S . Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome. J Korean Med Sci. 2018; 33(24):e169. PMC: 5990444. DOI: 10.3346/jkms.2018.33.e169. View

20.

Myall K, Mukherjee B, Castanheira A, Lam J, Benedetti G, Mak S . Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc. 2021; 18(5):799-806. PMC: 8086530. DOI: 10.1513/AnnalsATS.202008-1002OC. View